Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

This publication has 26 references indexed in Scilit:

• Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone
  Supportive Care in Cancer, 2009
• Giving Permission
  Journal of Clinical Oncology, 2008
• Glutathione S‐Transferase A1 Genetic Variants Reduce Busulfan Clearance in Children Undergoing Hematopoietic Cell Transplantation
  The Journal of Clinical Pharmacology, 2008
• A Randomized, Double-Blind Comparison of the NK1 Antagonist, Aprepitant, Versus Ondansetron for the Prevention of Postoperative Nausea and Vomiting
  Anesthesia & Analgesia, 2007
• Efficacy of oral casopitant mesylate, a novel neurokinin-1 receptor antagonist, with intravenous ondansetron HCl in the prevention of postoperative nausea and vomiting (PONV) in high-risk patients
  European Journal of Anaesthesiology, 2006
• Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
  Annals of Oncology, 2005
• Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers
  Current Medical Research and Opinion, 2005
• Consensus Guidelines for Managing Postoperative Nausea and Vomiting
  Anesthesia & Analgesia, 2003
• Pharmacology of the human metabolites of dolasetron, an antiemetic 5‐HT₃ receptor antagonist
  Drug Development Research, 1995
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990